India's Drug Regulator Requires Full Review for Globally Unapproved Drugs
India's drug regulator, CDSCO, has clarified that new drugs not approved anywhere globally must undergo the full domestic regulatory process, even if Indian patients participated in global clinical trials. Following a rise in applications to import and market such drugs still under foreign review, CDSCO's internal committee emphasized comprehensive evaluation of safety and efficacy under existing NDCT Rules, preventing companies from using trial participation as a shortcut for local approval.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (52/100). Lens Score 44/100.
Outlets measured: economictimes, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 11 Aug, 09:14 am. Other outlets followed.
- 1